2018 is shaping up to be a record year for private investing: VCs have already poured $73 billion into startups valued at $1 billion or more
- 65 companies have reached valuations of $1 billion or more in 2018, new data from Crunchbase reveals.
- Private investors have poured $73 billion into "unicorn" companies in the first 7 months of 2018 alone - just $15 billion short of the total funding for unicorns in all of 2017.
In Silicon Valley, startups valued at $1 billion or more are nicknamed "unicorns" because originally they were so few and far between. Advertisement
But, according to new data from Crunchbase, 2018 is quickly diminishing the rarity of the unicorn status: In the first seven months of the year alone, 65 companies have already achieved valuations of $1 billion or more.
If the trend continues, 2018 will be a record-making year for billion dollar companies."In the first seven months of 2018, investors put $73 billion into rounds for private venture-backed companies valued at $1 billion or more," Crunchbase reporter Joanna Glaser writes. "That's about three-fourths of the total for all of 2017, last tallied at $98 billion."
Among the companies achieving unicorn status are buzzy, US-based startups like electric scooter company Lime and e-cigarette purveyor Juul. As Crunchbase notes, cryptocurrency companies like mining chip producer Bitmain and crypto trading platform Circle are also unicorn newcomers.So far, the US and China are tied when it comes to companies achieving unicorn status. While a reported 26 companies have achieved billio-dollar valuations this year in both countries, Crunchbase notes that Chinese companies are typically slower to make their valuations publicly available, suggesting that China's startup growth could be greater than the US.However, it's worth remembering that big valuations, while often coveted by founders and investors alike, aren't necessarily always purely beneficial. As longtime Silicon Valley investor Elad Gil pointed out in a recent interview with Business Insider, a high valuation can often hurt a company's longterm growth.Advertisement
- Accenture's Q4 earnings miss estimate with low growth likely to continue for two more quarters
- Top stocks to watch— Tata Consumer, TCS, GAIL, Divi's Laboratories, SBI Life Insurance, ONGC, M&M, RITES and others
- Diabetes drug Metformin at centre of carcinogen-linked recalls in US
- A variety Of top shuttlecock sets
- Sporty badminton racket sets of 2